纵横研报
Ticker Detail

688217.SHG

¥22.73+1.70% 睿昂基因 Biotechnology
00Reports China 医疗健康
Shanghai Rightongene Biotechnology Co. Ltd. A
医疗健康 · 生物科技

Shanghai Rightongene Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products. The company provides gene and antigen testing for patients; and offers treatment plans, such as disease diagnosis, risk assessment, disease classification, targeted drug selection, and efficacy monitoring for for initial screening, follow-up, and re-examination of leukemia patients. It also offers molecular diagnostic kits for genes related to leukemia, lymphoma, solid tumors, and infectious diseases. In addition, it provides third-party medical testing services to various medical institutions, pharmaceutical companies, and individual patients, as well as gene testing research services to research hospitals, pharmaceutical companies, research institutions, and other third-party testing organizations. Shanghai Rightongene Biotechnology Co., Ltd. was founded in 2012 and is based in Shanghai, China.

MARKET 市值 1.24B CNY 52W ¥19.32 – ¥35.79 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY -28.7% ROE -7.8% 营业利润率 -23.3% 净利润率 -36.1%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制